Deal Watch: Teva Boosts CNS Portfolio With $3.2 Billion Purchase Of Auspex
Novartis raises its game in immuno-oncology through Aduro collaboration, while Merck Serono partners up with a CAR-T program at Intrexon. UnitedHealth grows its PBM business by acquiring Catamaran; Horizon expands its orphan drug portfolio in buyout of Hyperion.
You may also be interested in...
Novartis hopes its multi-year deal with Aduro Biotech to develop molecules to unlock dormant immune cells by targeting and activating a central signaling pathway called STING will allow it to make up for lost time and catch “the next wave” in immuno-oncology.
After disappearance last year of its drug hope DiaPep277 due to fraud, Germany’s Evotec is now looking to its Alzheimer’s MAO partnership with Roche and newly entered R&D alliance with Sanofi for future growth.
The drug store chain will purchase EnvisionRx, which serves over 21 million members and expects to manage 145 million pharmacy claims in 2015, for $2 billion in cash and stock.